Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistLiquidCapsule Manufacturing, LLC, an over-the-counter drug manufacturer in Tampa, Florida, was cited for significant Current Good Manufacturing Practice (CGMP) violations that rendered its drug products adulterated. During a June-July 2025 inspection, the FDA found that the company failed to adequately test incoming components for identity, purity, strength, and quality, and did not validate or establish the reliability of its component suppliers' test analyses at appropriate intervals, as required by 21 CFR 211.84. Notably, the firm failed to perform required USP identity testing on high-risk drug components to detect hazardous impurities and ensure compliance with relevant safety limits.